Abbott IndiaBOM:500488 +0.51%87 EBITDA Margin % is 32.55% as of Mar. 2026, which is 39% above its 10-year median of 23.50. GuruFocus rates BOM:500488 with a GF Score™ of 87/100 and a GF Value™ of ₹32,313.61 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 953 Drug Manufacturers companies, Abbott India ranks better than 88.04% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Abbott India's EBITDA for the
three
months ended in Mar. 2026 was ₹5,564 Mil. Abbott India's Revenue for the
three
months ended in Mar. 2026 was ₹17,095 Mil. Therefore, Abbott India's EBITDA margin for the quarter that ended in Mar. 2026 was 32.55%.
Abbott India (BOM:500488) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Abbott India EBITDA Margin % Related Terms
Abbott India EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Abbott India's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:500488 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Abbott India's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbott India EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Abbott India's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Abbott India's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott India (BOM:500488) has a EBITDA Margin % of 32.55% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Abbott India and its competitors. This is 39% above median its historical median of 23.50. Over the past decade, Abbott India's EBITDA Margin % has ranged from 15.73 to 31.47. According to the industry distribution chart, Abbott India ranks #114 out of 953 companies in the Drug Manufacturers industry, placing it in the top 12%.
Is Abbott India's EBITDA Margin % too high?
Abbott India's current EBITDA Margin % of 32.55% is 39% above median its 10-year median of 23.50. Over the past 10 years, this metric has ranged from a low of 15.73 to a high of 31.47. The Drug Manufacturers industry median EBITDA Margin % is 12.54. Abbott India's value of 32.55% is 159.6% above this industry median. Based on the distribution chart, Abbott India ranks #114 out of 953 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Abbott India has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abbott India's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Abbott India ranks #114 out of 953 companies for EBITDA Margin %. This places Abbott India in the top 12% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.54. Abbott India's value of 32.55% is 159.6% above this benchmark. Historically, Abbott India's own EBITDA Margin % has ranged from 15.73 to 31.47 over the past decade. While the company's 10-year median is 23.50 vs. the industry median of 12.54, Abbott India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abbott India's current EBITDA Margin % of 32.55% is 159.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Abbott India and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbott India's current EBITDA Margin % is 32.55%, which is 39% above median its own 10-year median of 23.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott India stock overvalued right now?
Based on GuruFocus' analysis, Abbott India (BOM:500488) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹32,313.61, compared to a current price of ₹25,566.95 — trading 20.9% below its estimated fair value. The current EBITDA Margin % is 32.55%, which is 39% above median its 10-year median of 23.50 and 159.6% above the Drug Manufacturers industry median of 12.54. Abbott India's overall GF Score™ is 87/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Abbott India (BOM:500488), the current EBITDA Margin % is 32.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott India (BOM:500488) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott India stock appears to be undervalued.
The current stock price of ₹25,566.95 is trading 20.9% below its estimated GF Value™ of ₹32,313.61.
GuruFocus considers Abbott India to be Modestly Undervalued.
Key valuation signals for BOM:500488:
EBITDA Margin %: 32.55% (39% above median its 10-year median of 23.50)
GF Value™: ₹32,313.61 vs. price of ₹25,566.95 (20.9% below fair value)
Industry Position: 159.6% above the Drug Manufacturers median (#114 of 953)
No single metric tells the full story. See the BOM:500488 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott India Ltd is a drug manufacturing company that offers products in diagnostics, medical devices, nutritionals, and branded generic pharmaceuticals. Its patient focus centers overwhelmingly on women's health and gastrointestine, gastroenterology, and hepatic care. Geographically, the majority of the company's revenue is generated in India.
87GF Score
Get the complete analysis for BOM:500488
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500488 has been successfully added to your 
